NCT07584213

Brief Summary

This is a real-world multicentre study to investigate the association between blood routine parameters combined with clinicopathological characteristics and breast cancer prognosis.

Trial Health

75
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
2,946

participants targeted

Target at P75+ for all trials

Timeline
11mo left

Started May 2026

Shorter than P25 for all trials

Geographic Reach
1 country

1 active site

Status
active not recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress6%
May 2026May 2027

Study Start

First participant enrolled

May 1, 2026

Completed
6 days until next milestone

First Submitted

Initial submission to the registry

May 7, 2026

Completed
1 day until next milestone

Primary Completion

Last participant's last visit for primary outcome

May 8, 2026

Completed
5 days until next milestone

First Posted

Study publicly available on registry

May 13, 2026

Completed
12 months until next milestone

Study Completion

Last participant's last visit for all outcomes

May 1, 2027

Expected
Last Updated

May 13, 2026

Status Verified

May 1, 2026

Enrollment Period

7 days

First QC Date

May 7, 2026

Last Update Submit

May 7, 2026

Conditions

Breast Cancer Invasive

Outcome Measures

Primary Outcomes (1)

  • Disease-free survival

    Disease-free survival time is defined as the time from the date of radical surgery until the date of the first occurrence of local/regional relapse, distant recurrence, contralateral breast cancer, second malignancy and death from any cause.

    From the date of radical surgery until time of event up to 3 years

Secondary Outcomes (2)

  • Recurrence-free survival

    From the date of radical surgery until time of event up to 3 years

  • Overall survival

    From the date of radical surgery until time of event up to 3 years

Study Arms (1)

Blood routine test

breast cancer patients with baseline blood routine results available

Procedure: blood routine test

Interventions

blood routine testPROCEDURE

blood routine test at baseline

Blood routine test

Eligibility Criteria

Age18 Years+
Sexfemale
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

Patients were pathologically diagnosed primary invasive breast cancer from October 2013 to December 2023. They had blood routine results.

You may qualify if:

  • Aged 18 years or older
  • Pathologically confirmed invasive primary breast cancer

You may not qualify if:

  • De novo stage IV breast cancer

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Renji Hospital, School of Medicine, Shanghai Jiaotong University

Shanghai, 200127, China

Location

Study Officials

  • Wenjin Yin

    Renji Hospital,School of Medicine, Shanghai Jiaotong University

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
RETROSPECTIVE
Sponsor Type
OTHER
Responsible Party
SPONSOR INVESTIGATOR
PI Title
Deputy Chief of Breast Surgery Department

Study Record Dates

First Submitted

May 7, 2026

First Posted

May 13, 2026

Study Start

May 1, 2026

Primary Completion

May 8, 2026

Study Completion (Estimated)

May 1, 2027

Last Updated

May 13, 2026

Record last verified: 2026-05

Locations

CN(1)